The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval. Read more to see a full investment analysis for IOVA ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

We are pleased to have the opportunity to present new data from the Phase 2 OVATION 2 Study of IMNN-001 in an oral presentation at ASCO’s Annual Meeting,” said Stacy Lindborg, Ph.D., president and ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is ...

The markers included morning cortisol levels, cytokines interleukin 1-β (IL-1β), as well as interleukin 2-R (IL-2R), blood ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

How do traumatic events affect our bodies? A new study set out to investigate by looking at three key areas: the autonomic ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...